Immunotherapy in breast cancer: current landscape and emerging trends.

Exp Hematol Oncol · 2025 · PMC12096519 · PMID 40405250

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Patients with PDL1+ (IC ≥1%) tumors showed a trend towards improved ORR and PFS compared to those with PDL1- (IC <1%) tumors (ORR, 39% vs 20%; PFS, 7.0 vs 3.7 months), but the number of patients was small and should be interpreted with caution [ 167 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.